RGNXREGENXBIO Inc.

RGNX Stock Price, Valuation & Chart | REGENXBIO Inc.

Compare

$9.600+0.28 (+3.00%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology RGNX intrinsic value RGNX calculated fair value vs price

Overview Financials Dividends Ratios

RGNX Historical price chart

RGNX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization496.29M

PE Ratio-2.53

EPS-3.79

Trading Volume866.26K

Today's High/Low9.7/9.2

Dividend Yield0.00

52 Week High/Low16.19/5.46

Shares Outstanding51.70M

RGNX Financial Statement

RGNX Analyst ratings

RGNX Analysis & performance metrics

RGNX Company profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in…

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery…

RGNX Management team

Name

Position

Olivier Danos Ph.D.

Executive Vice President & Chief Scientific Officer

Stephen Pakola M.D.

Executive Vice President & Chief Medical Officer

Ram Palanki Pharm.D.

Executive Vice President of Commercial Strategy & Operations

Shiva G. Fritsch

Chief Communications & People Officer

Patrick J. Christmas II, J.D.

Executive Vice President & Chief Strategy and Legal Officer

Mitchell Chan M.B.A.CFO

Executive Vice President & Chief Financial Officer

Curran M. Simpson M.S.CEO

President, Chief Executive Officer & Director

Craig MalzahnCTO

Executive Vice President, Product Development & Chief Technology Officer

Name

Position

Olivier Danos Ph.D.

Executive Vice President & Chief Scientific Officer

Stephen Pakola M.D.

Executive Vice President & Chief Medical Officer

Ram Palanki Pharm.D.

Executive Vice President of Commercial Strategy & Operations

Shiva G. Fritsch

Chief Communications & People Officer

Patrick J. Christmas II, J.D.

Executive Vice President & Chief Strategy and Legal Officer

Mitchell Chan M.B.A.CFO

Executive Vice President & Chief Financial Officer

Curran M. Simpson M.S.CEO

President, Chief Executive Officer & Director

Craig MalzahnCTO

Executive Vice President, Product Development & Chief Technology Officer

Management Team

Olivier Danos Ph.D.

Executive Vice President & Chief Scientific Officer

Stephen Pakola M.D.

Executive Vice President & Chief Medical Officer

Ram Palanki Pharm.D.

Executive Vice President of Commercial Strategy & Operations

Shiva G. Fritsch

Chief Communications & People Officer

Patrick J. Christmas II, J.D.

Executive Vice President & Chief Strategy and Legal Officer

Mitchell Chan M.B.A.CFO

Executive Vice President & Chief Financial Officer

Curran M. Simpson M.S.CEO

President, Chief Executive Officer & Director

Craig MalzahnCTO

Executive Vice President, Product Development & Chief Technology Officer

Management

Olivier Danos Ph.D.

Executive Vice President & Chief Scientific Officer

Stephen Pakola M.D.

Executive Vice President & Chief Medical Officer

Ram Palanki Pharm.D.

Executive Vice President of Commercial Strategy & Operations

Shiva G. Fritsch

Chief Communications & People Officer

Patrick J. Christmas II, J.D.

Executive Vice President & Chief Strategy and Legal Officer

Mitchell Chan M.B.A.CFO

Executive Vice President & Chief Financial Officer

Curran M. Simpson M.S.CEO

President, Chief Executive Officer & Director

Craig MalzahnCTO

Executive Vice President, Product Development & Chief Technology Officer

Total 8 executives

RGNX Frequently asked questions

What is REGENXBIO Inc. (RGNX) Stock Price?

Current stock price of REGENXBIO Inc. (RGNX) stock is $9.600. The stock price is +3.00% higher in the session. The intraday range can be seen from this page. Volume of REGENXBIO Inc. (RGNX) stock is 866.26K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the REGENXBIO Inc. (RGNX) stock price going up or down today?

The stock price of REGENXBIO Inc. (RGNX) can change with earnings, company news, and overall market sentiment. REGENXBIO Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the REGENXBIO Inc. stock expensive at its current price?

Whether REGENXBIO Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for RGNX on this page is -2.53. EPS on this page is -3.79. Compare those figures with peers and growth expectations before deciding if the current REGENXBIO Inc. price is justified.

How has the stock price of REGENXBIO Inc. (RGNX) performed historically?

Historical performance for REGENXBIO Inc. (RGNX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how RGNX reacted to past earnings and market events.

Should I buy REGENXBIO Inc. (RGNX) stock, at this price?

Buying REGENXBIO Inc. (RGNX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.